Current management of non-alcoholic fatty liver disease

Lisboa, Quelson Coelho; Costa, Silvia Marinho Ferolla; Couto, Cláudia Alves.
Rev. Assoc. Med. Bras. (1992) ; 62(9): 872-878, Dec. 2016. tab
Artículo en Inglés | LILACS | ID: biblio-829549

Documentos relacionados

  1. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
  2. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
  3. Obeticholic acid: towards first approval for NASH.
  4. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
  5. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
  6. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
  7. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
  8. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
  9. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
  10. Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.